Regeneron and Sanofi Study Dupilumab for Bullous Pemphigoid in Adults
A study is underway to evaluate the efficacy and safety of dupilumab in treating bullous pemphigoid, an autoimmune blistering disease.
Company
Pharmaceutical intelligence for Regeneron with 9 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.